ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Dose Reduction of Anti-Thymocyte Globulin for Kidney Transplant Induction: Possible Cost Savings?

M. Chaung, E. Hollinger, M. Brokhof, N. Alvey, L. Lineberger, N. Kenyon

Rush University Medical Center, Chicago, IL

Meeting: 2020 American Transplant Congress

Abstract number: D-004

Keywords: Economics, Elderly patients, Kidney transplantation

Session Information

Session Name: Poster Session D: Kidney Immunosuppression: Induction Therapy

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Based on the United Network of Organ Sharing (UNOS) annual report, there has been an increase in the number of adults ages 65-74 waiting for kidney transplants (KT). Currently, there is limited data regarding induction agents in this age group, but anti-thymocyte globulin (ATG) continues to be the agent of choice in this population. The optimal dose remains to be determined as transplant centers have reported using doses ranging from a total dose of 3 to 5 mg/kg. Lower doses of ATG are intriguing given the lower immunogenicity seen in older KT patients. Lower doses may provide a decrease in infectious complications and cancer and improved cost-savings without compromising efficacy. The purpose of this study is to compare efficacy outcomes in older KT recipients who received either low-dose ATG (LD-ATG) 3 mg/kg or high-dose ATG (HD-ATG) 5 mg/kg for induction. Secondary endpoints include infectious complications and a cost-savings analysis.

*Methods: This is a single center, retrospective cohort study at a large academic medical center. Patients age 65 years and older who received a KT between November 1, 2012 and September 1, 2018 and received either LD-ATG or HD-ATG for induction were included. Patients were excluded if they experienced death prior to discharge, received a prior transplant or received multi-organ transplantation. Data was compared using Fisher’s exact test and Chi-Squared.

*Results: A total of 115 patients were screened for inclusion and 51 patients were included in this study: 32 received LD-ATG and 19 received HD-ATG. Maintenance immunosuppression included tacrolimus, mycophenolate, and prednisone for both groups. No statistically significant difference in biopsy proven acute rejection (BPAR) at 12 months post-transplant was noted between LD-ATG and HD-ATG (3.1% (1/32) vs 10.5% (1/19), respectively). There was no statistically significant difference in side effects and patient and graft survival between groups. For one patient, the average cost of LD-ATG estimated to be $7000 compared to the average cost of HD-ATG was $12000.

*Conclusions: The results of this study demonstrate there is no significant difference in BPAR, patient, and graft survival when LD-ATG or HD-ATG is given as induction in older KT recipients. This shows potential for cost savings and lower risk of side effects in this specialized population.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Chaung M, Hollinger E, Brokhof M, Alvey N, Lineberger L, Kenyon N. Dose Reduction of Anti-Thymocyte Globulin for Kidney Transplant Induction: Possible Cost Savings? [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/dose-reduction-of-anti-thymocyte-globulin-for-kidney-transplant-induction-possible-cost-savings/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences